Cardiovascular and renal outcomes with varying degrees of kidney disease in high-risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE-O trial.
Ulagamadesan VenkatesanRajibul MianChinthanie RamasundarahettigeKelley R H BranchStephano Del PratoCarolyn Su Ping LamRenato D LopesRichard PratleyJulio RosenstockNaveed SattarPublished in: Diabetes, obesity & metabolism (2023)
In high-risk people with diabetes, eGFR, UACR, and KDIGO category have different relationships to incident cardiovascular and kidney outcomes. The beneficial effect of efpeglenatide on these outcomes is independent of kidney-related risk category.